LIFECORE BIOMEDICAL, INC. DE Business Summary

Lifecore Biomedical, Inc. operates as a specialized, fully integrated contract development and manufacturing organization (CDMO) focused on the formulation, aseptic fill, and finish of complex sterile injectable pharmaceutical products. The company generates revenue through two primary segments: its CDMO services, which provide end-to-end development and commercial manufacturing for third-party pharmaceutical and biotech partners, and its Hyaluronic Acid (HA) manufacturing business, which produces pharmaceutical-grade HA for use in ophthalmic, orthopedic, and aesthetic applications. Lifecore specializes in handling highly viscous materials and drug-device combinations, positioning itself as a premium boutique provider in a market dominated by larger, more diversified peers such as Catalent, Inc., Lonza Group, and Simtra BioPharma Solutions. By focusing on difficult-to-manufacture biologics and leveraging its proprietary fermentation and purification processes, Lifecore maintains a high-density niche as a pure-play U.S.-based manufacturer benefiting from the regionalization of pharmaceutical supply chains. The company is currently led by President and CEO Paul Josephs, who joined in 2024 with over 30 years of industry experience, including a previous tenure as CEO of Woodstock Sterile Solutions. The executive leadership team was further strengthened in late 2024 and early 2026 with the appointments of Chief Financial Officer Ryan Lake, formerly of Societal CDMO, and Chief Operating Officer Jim Moran. This management overhaul, supported by a board chaired by Craig Barbarosh and influenced by institutional investors such as 22NW, LP and Legion Partners, reflects the company’s strategic pivot from its legacy as a diversified holding company (formerly Landec Corporation) to a focused life sciences entity. The leadership is currently executing a capacity expansion strategy, including the integration of high-speed multi-purpose isolator fillers, to capture growing demand in the GLP-1 and ophthalmic therapeutic categories while targeting a significant increase in annual revenue potential.